Criminal Prosecution of Cell Therapeutics, Inc.
Cell Therapeutics, Inc., (CTI) of Seattle, Wash., paid $10.5 million to resolve allegations that it off-label marketed its anti-cancer drug, Trisenox, to treat various forms of cancer for which the drug had not been approved by the FDA. The settlement further resolved allegations that CTI paid kickbacks in the form of sham consulting agreements to induce physicians to prescribe Trisenox.
Source: HHS Health Care Fraud and Abuse Control Program, Annual Report for FY 2007
This article was posted on July 15, 2012.